Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION

v3.24.0.1
SEGMENT INFORMATION
 3 Months Ended
Jan. 31, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three months ended January 31, 2024 and 2023 and as of January 31, 2024 and October 31, 2023 (in thousands):

 

    2024     2023  
    For the Three Months Ended
January 31,		  
    2024     2023  
Net loss:                
CAR-T Therapeutics   $ (1,525 )   $ (911 )
Cancer Vaccines     (1,756 )     (958 )
Anti-Viral Therapeutics     -       (482 )
Other     (9 )     (3 )
Total   $ (3,290 )   $ (2,354 )
                 
Total operating costs and expenses   $ 3,609     $ 2,556  
Less non-cash share-based compensation     (1,260 )     (1,063 )
Operating costs and expenses excluding non-cash share-based compensation   $ 2,349     $ 1,493  
Operating costs and expenses excluding non-cash
share based compensation expense:		                
CAR-T Therapeutics   $ 1,128     $ 598  
Cancer Vaccines     1,213       588  
Anti-Viral Therapeutics     -       305  
Other     8       2  
Total   $ 2,349     $ 1,493  

 

    January 31,
2024		     October 31,
2023		  
Total assets:                
CAR-T Therapeutics   $ 12,124     $ 7,523  
Cancer Vaccines     13,162       17,215  
Anti-Viral Therapeutics     -       700  
Other     86       84  
Total   $ 25,372     $ 25,522  

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.